CRMD Q3 2025 Earnings — CorMedix Inc. Revenue & Financial Results | Market Cap Arena

CRMDCorMedix Inc.

$536M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$104M+810.2% YoY

Gross Profit

$93M89.3% margin

Operating Income

$51M49.2% margin

Net Income

$109M104.1% margin

EPS (Diluted)

$1.26

QoQ Revenue Growth

+162.4%

Cash Flow

Operating Cash Flow

$31M

Free Cash Flow

$30M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$751M

Total Liabilities

$377M

Stockholders' Equity

$374M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$104M	$11M	+810.2%
Gross Profit	$93M	$11M	+764.3%
Operating Income	$51M	-$3M	+1661.9%
Net Income	$109M	-$3M	+4009.6%

Revenue Segments

Product

$102M100%